A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology.

To establish whether the expression of markers of cell differentiation (CK7, CK14, CK20, GATA3), apoptosis (p53), proliferation (Ki67, STAG2) and peri-tumoural lymphocytes (CD3, CD8), provides specific information about urothelial carcinogenesis in neuro-urological patients with bladder cancer (NBC).

Tissue samples from NBC were retrieved from 15 centres in France and compared to control samples from non neuro-urological patients with bladder cancer (NNBC) and from neuro-urological patients without bladder cancer (NB). The expression of CK7, CK14, CK20, GATA3, p53, Ki67, STAG2, CD3 and CD8 markers was analysed using immunohistochemistry of tissue microarray sections.

Overall, tissue samples from 124 patients were included in the study (n = 72 NBC, n = 26 NNBC and n = 26 NB). Muscle invasive bladder cancer (MIBC) was found in 52 NBC patients (72.2%) and squamous cell differentiation in 9 (12.5%). In NBC samples, the expression of CK20 and GATA3 was significantly more frequent in NMIBC compared to MIBC (p = 0.015 and p = 0.004, respectively). CK20 and GATA3 were significantly more expressed in NBC compared to NNBC (p < 0.001 and p = 0.010, respectively). The expression of CK14, Ki67, CD3 and CD8 was significantly more frequent in NBC than in NNBC samples (p = 0.005, p < 0.001, p < 0.001 and p < 0.001, respectively). The expression of CD3 and CD8 was similar in NBC and NB samples.

In NBC, markers of basal differentiation, proliferation and peri-tumoural lymphocytes were significantly more expressed compared to NNBC controls. These results suggest the aggressiveness of NBC and the role of chronic inflammation in the carcinogenesis of bladder cancer in neuro-urological patients.

World journal of urology. 2022 Feb 09 [Epub ahead of print]

Floriane Michel, Fabiana Cancrini, Géraldine Cancel-Tassin, Xavier Gamé, Eric Huyghe, Aurélien Rock, Grégoire Léon, Audrey Uzan, François-Régis Desfemmes, Benoît Peyronnet, Jérémy Fallot, Priscilla Léon, Emmanuel Rolland, Marie-Aimée Perrouin-Verbe, Jacques Wodey, Grégoire Capon, Gilles Karsenty, Morgan Rouprêt, Olivier Cussenot, Hussa Alshehhi, Eva Comperat, Véronique Phé

Department of Urology and Kidney Transplantation, Aix-Marseille University, La Conception Hospital, Assistance Publique-Hôpitaux de Marseille, 147 Boulevard Baille, 13005, Marseille, France. ., Sorbonne University, GRC5 Predictive Onco-urology, Assistance Publique-Hôpitaux de Paris, Paris, France., Department of Urology, CHU Rangueil, Université Paul Sabatier Toulouse III, Toulouse, France., Department of Urology, Groupe Hospitalier de L'Institut Catholique Lillois, Lille, France., Department of Urology and Transplantation, CHU de Caen, Caen, France., Department of Urology, Sorbonne University, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Department of Urology, Hôpital d'instruction Des Armées du Val de Grace, Paris, France., Department of Urology, University of Rennes, Rennes, France., Department of Urology, Royal Prince Alfred Hospital, Sydney, NSW, Australia., Department of Urology, Clinique Urologie Royan, Royan, France., Department of Urology, Clinique Toulouse Lautrec, Albi, France., Department of Urology and Transplantation Surgery, Nantes University Hospital, Nantes, France., Department of Urology, Clinique Rhône Durance, Avignon, France., Department of Urology, University of Bordeaux, Bordeaux, France., Department of Urology and Kidney Transplantation, Aix-Marseille University, La Conception Hospital, Assistance Publique-Hôpitaux de Marseille, 147 Boulevard Baille, 13005, Marseille, France., Department of Pathology, Sorbonne University, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

email news signup